Corey Cutler, MD, MPH, and Hannah Choe, MD, provide an overview of chronic graft-vs-host disease (GVHD) and identify characteristics that differentiate it from acute GVHD.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.